| Website | igenica.com |
| Category | BioTech |
| Phone | 650-697-4900 |
| info@igenica.com | |
| Employees | |
| Founded | 2008 |
| TOTAL | $57M |
| FUNDING TOTAL | $57M |
| Series B, 6/10 The Column Group OrbiMed Advisors 5AM Ventures | $24M |
| Series C, 6/12 Third Rock Ventures The Column Group OrbiMed Advisors 5AM Ventures | $33M |
Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. Although recombinant monoclonal antibodies (mAbs) are considered to be one of the most promising immunologic approaches to therapy, relatively few products have been approved for use in humans. In fact, there appears to be an increasing reliance on an ageing and overlapping portfolio of mAb drugs and drug targets, discovered by a process that has evolved very little over the past two decades. Igenica contends that the key to next generation mAb-based medicines lies in both the identification of new targets and the deployment of novel antibody discovery approaches. To this end, the company has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective mAb drug candidates.
